Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Evangelia Bei has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fabry disease due to D313Y variant with renal failure and possible cardiac involvement: a case report

    by Evangelia Bei, Alexios S Antonopoulos, Georgios Tsivgoulis, Charalambos Vlachopoulos

    This is a case report of a patient with Anderson–Fabry disease (AFD) due to the D313Y variant on the a-galactosidase A (GLA) gene on migalastat treatment and severe chronic kidney disease referred to our unit to assess possible cardiac involvement. A 53-year-old man with chronic kidney disease due to AFD and a medical history of revascularized coronary artery disease, chronic atrial fibrillation, and arterial hypertension was referred to our unit for evaluation of possible cardiac involvement in the context of AFD. Biochemical evaluation reported reduced serum alpha-galactosidase A activity and borderline abnormal serum lyso-Gb3 enzyme activity. The patient had also history of acroparesthesias, dermatological presentation of multiple angiokeratomas, severe kidney impairment with an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73m² by the age of 16, and microalbuminuria that cumulatively set the diagnosis of AFD. Transthoracic echocardiogram showed left ventricular concentric hypertrophy with left ventricular ejection fraction of 45%. Cardiac magnetic resonance showed findings in keeping with ischaemic heart disease (IHD), i.e. akinesia and subendocardial scarring of the basal anterior and the entirety of the septum and the true apex; in addition, there was severe asymmetrical hypertrophy of the basal anteroseptum (max 18 mm), evidence of low-grade myocardial inflammation, and mid-wall fibrosis of the basal inferior and inferolateral wall, suggesting a cardiomyopathic process–myocardial disease which could not be explained solely by IHD or well-controlled hypertension. This is the first case of possible cardiac involvement in a patient with AFD due to the D313Y variant. This case demonstrates the diagnostic challenges of cardiac involvement in AFD, especially in the presence of a concomitant underlying pathology.


  • Open Access

    Impact of Evolution of Self-Expandable Aortic Valve Design: Peri-Operative and Short-Term Outcomes

    by Evangelia Bei, Vasileios Voudris, Konstantinos Kalogeras, Evangelos Oikonomou, Ioannis Iakovou, Ilias Kosmas, Charalampos Kalantzis, Michael-Andrew Vavuranakis, Panteleimon Pantelidis, George Lazaros, et al.

    A few data exist on the differences of implantable aortic valve bio-prostheses. We investigate three generations of self-expandable aortic valves in terms of the outcomes. Patients undergoing transcatheter aortic valve implantation (TAVI) were allocated into three groups according to the valve type: group A (CoreValveTM), group B (EvolutTMR) and group C (EvolutTMPRO). The implantation depth, device success, electrocardiographic parameters, need for permanent pacemaker (PPM), and paravalvular leak (PVL) were assessed. In the study, 129 patients were included. The final implantation depth did not differ among the groups (p = 0.07). CoreValveTM presented greater upward jump of the valve at release (2.88 ± 2.33 mm vs. 1.48 ± 1.09 mm and 1.71 ± 1.35 mm, for groups A, B, and C, respectively, p = 0.011). The device success (at least 98% for all groups, p = 1.00) and PVL rates (67% vs. 58%, vs. 60% for groups A, B, and C, respectively, p = 0.64) did not differ. PPM implantation within 24 h (33% vs. 19% vs. 7% for groups A, B, and C, respectively, p = 0.006) and until discharge (group A: 38% vs. group B: 19% and group C: 9%, p = 0.005) was lower in the newer generation valves. Newer generation valves present better device positioning, more predictable deployment, and fewer rates of PPM implantation. No significant difference in PVL was observed.


  • Open Access

    Hypertensive crisis and pulmonary edema following rituximab-induced anaphylaxis

    by Stylian Brili, Evangelia Bei, Nikolas G Kounis, Christina Chrysohoou, Christos-Konstantinos Antoniou, Flora Kontopidou, Laura Bonfanti, Gianfranco Cervellin, Dimitrios Tousoulis Tousoulis, Constantinos Tsioufis

    Rituximab is a monoclonal antibody against the protein CD20. Various lymphomas as well as non-malignant immune disorders are treated with this antibody. Hypersensitivity reactions associated with the use of rituximab include urticaria, hypotension, chest tightness, vomiting, oxygen desaturation and bronchospasm. A very uncommon case of hypertensive crisis and pulmonary edema following rituximab-induced hypersensitivity reaction in an 80-year-old man receiving rituximab for non-Hodgkin lymphoma is reported. Anaphylaxis manifesting as coronary vasospasm following drug treatment, including rituximab, could be proved a serious condition in patients who need specific treatment. In these patients desensitization protocols seem to be mandatory. (www.actabiomedica.it)


  • IMPACT OF ATRIAL FIBRILLATION ON EMBOLIC HIGH-INTENSITY TRANSIENT SIGNALS DURING TAVI. A TRANSCRANIAL DOPPLER STUDY

    by Charalampos Kalantzis, Michael Vavuranakis, Konstantinos Kalogeras, Evangelia Bei, Carmen Maria Moldovan, Efstratios Katsianos, Gerasimos Siasos, Dimitris Tousoulis, Konstantinos Tsioufis, Manolis Vavuranakis

  • One‐year clinical and echocardiographic outcomes of direct implantation of a self‐expanding valve

    by Georgios Benetos, Maria Karmpalioti, Maria Drakopoulou, Konstantinos Stathogiannis, Maria Xanthopoulou, George Latsios, Andreas Synetos, Evangelia Bei, Vassilis Voudris, Ioannis Iakovou, et al.

    Objective: To present 1 year clinical and echocardiographic outcomes of the randomized DIRECT (Pre‐dilatation in Transcatheter Aortic Valve Implantation Trial) trial.Background: Intermediate‐term data from randomized studies investigating the safety and efficacy of direct implantation are lacking.Methods: DIRECT trial randomized 171 consecutive patients with severe aortic stenosis at four tertiary centers to undergo TAVI with the use of self‐expanding prostheses with (pre‐BAV) or without pre‐dilatation (no‐BAV). The primary endpoint was device success according to the VARC‐2 criteria. All patients underwent a clinical and echocardiographic follow‐up at 1 year. All‐cause and cardiac mortality, stroke, heart failure hospitalization, and new pacemaker implantation were recorded.Results: At 1 year, four deaths were recorded in pre‐BAV group (4.7%) and three deaths in no‐BAV group (3.5%). There was no difference in Kaplan–Meier plots between the two groups in all‐cause mortality at 1 year (log‐rank p = .72). Similarly, there was no difference in the incidence of permanent pacemaker implantation between the two groups at 1 year (27/67–40.3% in no‐BAV group versus 20/69–29% in pre‐BAV group, log‐rank p = .24). There was no significant difference between pre‐BAV and no BAV group in aortic valve area (1.84 ± 0.39 cm2 vs. 1.85 ± 0.44 cm2, p = .90), mean aortic valve gradient (8.36 ± 5.04 vs. 8.00 ± 4.04 mmHg, p = .65) and moderate or severe paravalvular regurgitation (5–6.6 vs. 4–5.7%, respectively) at 1 year. The same applied independently from the performance of post‐dilatation at baseline.Conclusions: Direct, without pre‐dilatation, implantation of a self‐expanding valve has no impact on one‐year clinical and echocardiographic outcomes, independently also from the baseline performance of post‐dilatation.


  • Open Access

    Transient constrictive pericarditis following acute idiopathic pericarditis. A case report

    by George Lazaros, Konstantinos Konstantinou, Oyrania Katsarou, Areti Koumeli, Evelina Bei, Dimitrios Tousoulis